公开(公告)号：US10240201B2

公开(公告)日：2019-03-26

申请号：US15120433

申请日：2015-02-20

Applicant: Healios K.K.

Inventor： Masayo Takahashi ,  Sunao Sugita

IPC: C12Q1/6883 ,  A61K35/30 ,  G01N33/68 ,  A61L27/36

Abstract: The present invention provides an agent for treating ophthalmic diseases and a screening method for an agent for treating ophthalmic diseases and the like. The present invention also provides a method for predicting rejection associated with transplantation of retinal pigment epithelial cell to patients with ophthalmic diseases.

公开(公告)号：US20170009298A1

公开(公告)日：2017-01-12

申请号：US15120433

申请日：2015-02-20

Applicant: Healios K.K.

Inventor： Masayo Takahashi ,  Sunao Sugita

IPC: C12Q1/68 ,  G01N33/68 ,  A61L27/36

CPC classification number: C12Q1/6883 ,  A61K35/30 ,  A61L27/3604 ,  A61L27/3666 ,  A61L2430/16 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/6863 ,  G01N33/6866 ,  G01N33/6893 ,  G01N2333/57 ,  G01N2333/96433 ,  G01N2500/10 ,  G01N2800/245

Abstract: The present invention provides an agent for treating ophthalmic diseases and a screening method for an agent for treating ophthalmic diseases and the like. The present invention also provides a method for predicting rejection associated with transplantation of retinal pigment epithelial cell to patients with ophthalmic diseases.

Abstract translation: 本发明提供了治疗眼科疾病的药剂和眼科疾病等的治疗剂的筛选方法。 本发明还提供了一种用于预测与眼部疾病患者视网膜色素上皮细胞移植相关的排斥反应的方法。

公开(公告)号：US20160244721A1

公开(公告)日：2016-08-25

申请号：US15028158

申请日：2014-10-09

Applicant: HEALIOS K.K. ,  OSAKA UNIVERSITY

Inventor： Masanori SAWADA ,  Kiyotoshi SEKIGUCHI

IPC: C12N5/079 ,  A61K35/30

CPC classification number: C12N5/0621 ,  A61K9/0048 ,  A61K35/30 ,  C12N2501/727 ,  C12N2506/45 ,  C12N2509/00 ,  C12N2533/52

Abstract: The present invention provides a method of purifying highly pure retinal pigment epithelial cells from a cell population obtained by induction of differentiation of pluripotent stem cells into retinal pigment epithelial cells, by a simple and easy operation in a short period. The purification method of the present invention includes a step of introducing a cell population containing retinal pigment epithelial cells obtained by differentiation induction of pluripotent stem cells on laminin or a fragment thereof on a filter, and obtaining a cell population that passed the filter.

Abstract translation: 本发明提供了通过在短时间内简单且容易的操作诱导将多能干细胞分化为视网膜色素上皮细胞而获得的细胞群中纯化高纯度视网膜色素上皮细胞的方法。 本发明的纯化方法包括将通过将多能干细胞分化诱导获得的视网膜色素上皮细胞的细胞群导入到过滤器上的层粘连蛋白或其片段上，获得通过过滤器的细胞群的步骤。

公开(公告)号：US20250122474A1

公开(公告)日：2025-04-17

申请号：US18834874

申请日：2023-01-30

Applicant: HEALIOS K.K.

Inventor： Kenji KURACHI ,  Masashi YAMADA ,  Hironobu KIMURA ,  Kouichi TAMURA

IPC: C12N5/0783 ,  C12N5/00

Abstract: The present invention provides a novel method for producing natural killer (NK) cells, which enables production of a large amount of high-quality NK cells easily, inexpensively, and safely in a short period of time from pluripotent stem cells. Specifically, a method for producing NK cells is provided, including (1) a step of forming pluripotent stem cell spheres having an average particle size of not less than 200 μm in a first medium; (2) a step of inducing the pluripotent stem cell spheres formed in step (1) into a cell population including hematopoietic progenitor cells by three-dimensional culture using a second medium; and (3) a step of inducing the cell population including hematopoietic progenitor cells obtained in step (2) into a cell population including NK cells by three-dimensional culture using a third medium, wherein the steps (1) to (3) are performed by a perfusion culture method.

公开(公告)号：US11524035B2

公开(公告)日：2022-12-13

申请号：US16313694

申请日：2017-06-29

Applicant: HEALIOS K.K. ,  SUMITOMO PHARMA CO., LTD.

Inventor： Dai Otagiri ,  Tadao Maeda

IPC: A61K35/30 ,  A01N1/02 ,  A61K9/10 ,  A61K47/02 ,  A61K47/34 ,  A61L27/38 ,  A61K47/10 ,  A61K47/20 ,  A61K47/42 ,  A61L27/36 ,  A61L27/50

Abstract: The present invention, in which RPE cells are suspended in a medium pharmaceutically acceptable as an ocular irrigating/washing solution and containing a poloxamer, achieves improvement of the post-thawing survival rate of cryopreserved RPE cells, improvement of the photoreceptor cell protection effect by RPE cell transplanted immediately after thawing, and prevention of loss of RPE cells in various steps from thawing to transplantation.

公开(公告)号：US20180258388A1

公开(公告)日：2018-09-13

申请号：US15757202

申请日：2016-09-08

Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD. ,  HEALIOS K.K.

Inventor： Satoshi ANDO ,  Takao KURODA

IPC: C12N5/079 ,  A61K35/30 ,  G01N33/50

CPC classification number: C12N5/0621 ,  A61K35/30 ,  A61K35/545 ,  A61L27/00 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/999 ,  C12N2506/03 ,  C12Q1/02 ,  G01N33/5014 ,  G01N33/5044

Abstract: The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. The method of the present invention for producing retinal pigment epithelial cells includes the following steps:(1) a first step for culturing a pluripotent stem cell in a medium comprising an FGF receptor inhibitor and/or an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.

公开(公告)号：US20250041418A1

公开(公告)日：2025-02-06

申请号：US18709373

申请日：2022-11-10

Applicant: HEALIOS K.K.

Inventor： Kouichi TAMURA ,  Hironobu KIMURA ,  Tomonori HOSOYA ,  Masashi YAMADA

IPC: A61K39/00 ,  C07K14/52 ,  C07K14/715 ,  C12N5/0783

Abstract: The present invention provides a pluripotent stem cell expressing the following (a) and (b): (a) an exogenous gene encoding CC chemokine receptor 2 type B(CCR2B) (b) an exogenous gene encoding CC chemokine ligand 19 (CCL19), or an NK cell derived from the pluripotent stem cell or a progenitor cell thereof.

公开(公告)号：US20230287342A1

公开(公告)日：2023-09-14

申请号：US18295428

申请日：2023-04-04

Applicant: SUMITOMO PHARMA CO., LTD. ,  HEALIOS K.K.

Inventor： Satoshi ANDO ,  Takao KURODA

IPC: C12N5/079 ,  A61K35/30 ,  C12Q1/02 ,  A61L27/00 ,  A61K35/545 ,  G01N33/50

CPC classification number: C12N5/0621 ,  A61K35/30 ,  C12Q1/02 ,  A61L27/00 ,  A61K35/545 ,  G01N33/5014 ,  G01N33/5044 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/999 ,  C12N2506/03

Abstract: The invention provides a method for producing a retinal pigment epithelial cell by (1) maintaining and/or expanding human pluripotent stem cells comprising culturing the human pluripotent stem cells in the absence of a feeder cell in a medium comprising a factor for maintaining an undifferentiated state, (2) a first step for culturing the maintained and/or expanded human pluripotent stem cells in a medium comprising a MEK inhibitor in the absence of feeder cells for a period of not less than 2 days and not more than 30 days, wherein the culture condition in the first step is a condition sufficient for inducing gene expression of at least one eye field transcription factor, and (3) a second step for culturing the cells obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.

公开(公告)号：US20230203445A1

公开(公告)日：2023-06-29

申请号：US18000030

申请日：2021-05-26

Applicant: HEALIOS K.K.

Inventor： Kouichi TAMURA ,  Hironobu KIMURA ,  Tomonori HOSOYA ,  Norihiro TSUNEYOSHI

IPC: C12N5/0789 ,  C12N15/90 ,  C12N15/11 ,  C12N9/22

CPC classification number: C12N5/0647 ,  C12N15/907 ,  C12N15/11 ,  C12N9/22 ,  C12N2506/45 ,  C12N2310/20 ,  C12N2800/80 ,  C12N2501/26 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2502/1358

Abstract: The present invention provides a highly functional hypoimmunogenic cell, namely, a hypoimmunogenic human cell

(1) lacking an endogenous gene encoding an α chain of human leukocyte antigen (HLA) class Ia,
(2) lacking an endogenous gene encoding HLA class II or an expression regulator thereof,
(3) containing an exogenous gene encoding an α chain of HLA class Ib,
(4) containing an exogenous gene encoding human PD-L1, and
(5) containing an exogenous gene encoding human PD-L2.

公开(公告)号：US11649432B2

公开(公告)日：2023-05-16

申请号：US15757202

申请日：2016-09-08

Applicant: SUMITOMO PHARMA CO., LTD. ,  HEALIOS K.K.

Inventor： Satoshi Ando ,  Takao Kuroda

IPC: A61K35/30 ,  C12N5/079 ,  C12Q1/02 ,  A61L27/00 ,  A61K35/545 ,  G01N33/50

CPC classification number: C12N5/0621 ,  A61K35/30 ,  A61K35/545 ,  A61L27/00 ,  C12Q1/02 ,  G01N33/5014 ,  G01N33/5044 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/999 ,  C12N2506/03

Abstract: The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. The method of the present invention for producing retinal pigment epithelial cells includes the following steps:
(1) a first step for culturing a pluripotent stem cell in a medium comprising an FGF receptor inhibitor and/or an MEK inhibitor for a period of not more than 30 days, and
(2) a second step for culturing the cell obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.